Isunakinra not checked

Buzzard Pharmaceuticals · EBI-005

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total

What this is

How it works
How it works isn't classified yet
Tested for
Colorectal Cancer Metastatic
Main trialPhase 2
“This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this study the investigators are testing a new type of immunotherapy, the potent IL-1 inhibitor isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this treatment to work in this treatment resistant type of tumor.”In the company’s words, NCT06634875 on ClinicalTrials.gov
Other names
EBI-005

Other drugs for Colorectal Cancer Metastatic

All 393 drugs for Colorectal Cancer Metastatic

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 30 Jun 2027 Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
Phase 1/2Completed 31 Dec 2023 Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Isunakinra

Following is part of Solo: you see every change to Isunakinra the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in